Old Web
English
Sign In
Acemap
>
authorDetail
>
Mengyao Li
Mengyao Li
Merck & Co.
Medicine
Response rate (survey)
Oncology
Internal medicine
Follicular lymphoma
4
Papers
50
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Immunogenicity of pembrolizumab in patients with advanced tumors
2019
Journal for ImmunoTherapy of Cancer
Marianne van Vugt
Julie A. Stone
Rik de Greef
Ellen Snyder
Leslie Lipka
David C. Turner
Anne Chain
Mallika Lala
Mengyao Li
Seth Robey
Anna G. Kondic
Dinesh P. de Alwis
Kapil Mayawala
Lokesh Jain
Tomoko Freshwater
Show All
Source
Cite
Save
Citations (12)
A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.
2018
Journal of Clinical Oncology
Mallika Lala
Mengyao Li
Vikram Sinha
Dinesh de Alwis
Elliot Chartash
Lokesh Jain
Show All
Source
Cite
Save
Citations (25)
Relationship between response rates and median progression‐free survival in non‐Hodgkin's lymphoma: A meta‐analysis of published clinical trials
2018
Hematological Oncology
Naveen Mangal
Ahmed Salem
Mengyao Li
Rajeev M. Menon
Kevin J. Freise
Show All
Source
Cite
Save
Citations (11)
Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients.
2017
Medicine
Mengyao Li
Nimita Dave
Ahmed Hamed Salem
Kevin J. Freise
Show All
Source
Cite
Save
Citations (2)
1